In the retrospective ROSET-BM study (12), T-DXd was also shown to have promising efficacy in HER2+ BC patients with active brain metastases as well as leptomeningeal carcinomatosis, which are associated with poor prognosis and remain difficult to treat (4, 13). The gene discussed is ERBB2; the disease is breast cancer.